A 68-year-old man presents with tense, intact bullae on the flexural surfaces of both forearms and inner thighs for 3 weeks. Examination reveals urticarial lesions and erythematous plaques interspersed with bullae. Serum shows IgG and IgA antibodies against basement membrane zone. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis and Confirmation Strategy **Key Point:** In a patient with clinical features strongly suggestive of bullous pemphigoid and serum antibodies against the basement membrane zone (BMZ), **Direct Immunofluorescence (DIF) on perilesional skin** is the gold standard next step for definitive diagnosis — it is the single most important confirmatory test before initiating systemic corticosteroids. ### Why Direct Immunofluorescence (DIF) on Perilesional Skin is the Best Next Step 1. **Gold standard for bullous pemphigoid**: DIF on perilesional (non-blistered, adjacent) skin demonstrates **linear IgG and C3 deposits along the BMZ** — this is pathognomonic for bullous pemphigoid (Fitzpatrick's Dermatology, 9e; Rook's Textbook of Dermatology). 2. **Serology (IIF) already done**: The stem states serum IgG and IgA antibodies against BMZ are present — this represents indirect immunofluorescence (IIF), which is suggestive but not confirmatory. DIF on tissue is the definitive next step. 3. **Perilesional skin is preferred**: Biopsy from the edge of a lesion (perilesional) rather than the center of a bulla gives the clearest linear immunofluorescence pattern, as antibodies are concentrated at the intact dermal–epidermal junction adjacent to active lesions. 4. **Differentiates subepidermal blistering diseases**: DIF distinguishes bullous pemphigoid (linear IgG + C3) from Linear IgA disease (linear IgA), epidermolysis bullosa acquisita, and mucous membrane pemphigoid — all of which can present similarly clinically. ### Why Option C (Histopathology) is Less Specific as the "Next Step" While histopathology (H&E) showing a subepidermal blister with eosinophil-rich infiltrate is supportive, it is **not specific** for bullous pemphigoid and cannot differentiate it from other subepidermal blistering disorders. DIF is the definitive test and is the standard of care as the next diagnostic step when clinical and serological features are already present. ### Differential Diagnosis Clarified by DIF | Feature | Bullous Pemphigoid | Pemphigus Vulgaris | Linear IgA Disease | | --- | --- | --- | --- | | **Blister level** | Subepidermal | Intraepidermal (suprabasal) | Subepidermal | | **DIF pattern** | Linear IgG + C3 at BMZ | Intercellular IgG ("tombstone") | Linear IgA at BMZ | | **Histology** | Eosinophil-rich infiltrate | Acantholysis | Neutrophil-rich infiltrate | **Clinical Pearl:** IIF on serum (already done here) is a screening tool; DIF on perilesional skin biopsy is the confirmatory gold standard for bullous pemphigoid diagnosis (Fitzpatrick's Dermatology, 9e, Ch. 30). **High-Yield:** Always biopsy **perilesional** skin (not the bulla itself) for DIF — the bulla center may show false-negative results due to antibody consumption and tissue disruption at the blister site.